O`Brien, S, Schiller, G, Lister, J, Damon, L, Goldberg, S, Aulitzky, W, Ben‐Yehuda, D, Stock, W, Coutre, S, Douer, D, et al. High‐dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome‐negative acute lymphoblastic leukemia. J Clin Oncol 2013, 31:676–683.
Stathopoulos, GP, Antoniou, D, Dimitroulis, J, Michalopoulou, P, Bastas, A, Marosis, K, Stathopoulos, J, Provata, A, Yiamboudakis, P, Veldekis, D, et al. Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non‐small‐cell lung cancer: a randomized phase III multicenter trial. Ann Oncol 2010, 21:2227–2232.
Amadori, D, Milandri, C, Comella, G, Saracchini, S, Salvagni, S, Barone, C, Bordonaro, R, Gebbia, V, Barbato, A, Serra, P, et al. A phase I/II trial of non‐pegylated liposomal doxorubicin, docetaxel and trastuzumab as first‐line treatment in HER‐2‐positive locally advanced or metastatic breast cancer. Eur J Cancer 2011, 47:2091–2098.
Ullrich, E, Koch, J, Cerwenka, A, Steinle, A. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology 2013, 2:e26097.
Koebel, CM, Vermi, W, Swann, JB, Zerafa, N, Rodig, SJ, Old, LJ, Smyth, MJ, Schreiber, RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903–907.
Dunn, GP, Old, LJ, Schreiber, RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137–148.
Burgess, R. Medical applications of nanoparticles and nanomaterials. Stud Health Technol Inform 2009, 149:257–283.
Mailander, V, Landfester, K. Interaction of nanoparticles with cells. Biomacromolecules 2009, 10:2379–2400.
Dobrovolskaia, MA, McNeil, SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007, 2:469–478.
Dobrovolskaia, MA, Aggarwal, P, Hall, JB, McNeil, SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 2008, 5:487–495.
Aggarwal, P, Hall, JB, McLeland, CB, Dobrovolskaia, MA, McNeil, SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009, 61:428–437.
Kumari, A, Yadav, SK. Cellular interactions of therapeutically delivered nanoparticles. Expert Opin Drug Deliv 2011, 8:141–151.
Wegmann, F, Gartlan, KH, Harandi, AM, Brinckmann, SA, Coccia, M, Hillson, WR, Kok, WL, Cole, S, Ho, LP, Lambe, T. Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat Biotechnol 2012, 30:883–888.
Ma, W, Chen, M, Kaushal, S, McElroy, M, Zhang, Y, Ozkan, C, Bouvet, M, Kruse, C, Grotjahn, D, Ichim, T, et al. PLGA nanoparticle‐mediated delivery of tumor antigenic peptides elicits effective immune responses. Int J Nanomedicine 2012, 7:1475–1487.
Un, K, Kawakami, S, Suzuki, R, Maruyama, K, Yamashita, F, Hashida, M. Suppression of melanoma growth and metastasis by DNA vaccination using an ultrasound‐responsive and mannose‐modified gene carrier. Mol Pharm 2011, 8:543–554.
Roth, A, Rohrbach, F, Weth, R, Frisch, B, Schuber, F, Wels, WS. Induction of effective and antigen‐specific antitumour immunity by a liposomal ErbB2/HER2 peptide‐based vaccination construct. Br J Cancer 2005, 92:1421–1429.
Ghiringhelli, F, Puig, PE, Roux, S, Ghiringhelli, F, Puig, PE, Roux, S, Parcellier, A, Schmitt, E, Solary, E, Kroemer, G, et al. Tumor cells convert immature myeloid dendritic cells into TGF‐β‐secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005, 202:919–929.
Toraya‐Brown, S, Sheen, MR, Baird, JR, Barry, S, Demidenko, E, Turk, MJ, Hoopes, PJ, Conejo‐Garcia, JR, Fiering, S. Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy. Integr Biol (Camb) 2012, 5:159–171.
Beck, B, Dorfel, D, Lichtenegger, FS, Geiger, C, Lindner, L, Merk, M, Schendel, DJ, Subklewe, M. Effects of TLR agonists on maturation and function of 3‐day dendritic cells from AML patients in complete remission. J Transl Med 2011, 9:151.
Huang, Z, Yang, Y, Jiang, Y, Shao, J, Sun, X, Chen, J, Dong, L, Zhang, J. Anti‐tumor immune responses of tumor‐associated macrophages via toll‐like receptor 4 triggered by cationic polymers. Biomaterials 2013, 34:746–755.
Cubillos‐Ruiz, JR, Engle, X, Scarlett, UK, Martinez, D, Barber, A, Elgueta, R, Wang, L, Nesbeth, Y, Durant, Y, Gewirtz, AT, et al. Polyethylenimine‐based siRNA nanocomplexes reprogram tumor‐associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 2009, 119:2231–2244.
Cubillos‐Ruiz, JR, Baird, JR, Tesone, AJ, Rutkowski, MR, Scarlett, UK, Camposeco‐Jacobs, AL, Anadon‐Arnillas, J, Harwood, NM, Korc, M, Fiering, SN, et al. Reprogramming tumor‐associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res 2012, 72:1683–1693.
Grzelinski, M, Urban‐Klein, B, Martens, T, Lamszus, K, Bakowsky, U, Höbel, S, Czubayko, F, Aigner, A. RNA interference‐mediated gene silencing of pleiotrophin through polyethylenimine‐complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 2006, 17:751–766.
Urban‐Klein, B, Werth, S, Abuharbeid, S, Czubayko, F, Aigner, A. RNAi‐mediated gene‐targeting through systemic application of polyethylenimine (PEI)‐complexed siRNA in vivo. Gene Ther 2005, 12:461–466.
Camacho, AI, Da Costa, MR, Tamayo, I, de Souza, J, Lasarte, JJ, Mansilla, C, Esparza, I, Irache, JM, Gamazo, C. Poly(methyl vinyl ether‐co‐maleic anhydride) nanoparticles as innate immune system activators. Vaccine 2011, 29:7130–7135.
Bal, SM, Slutter, B, Verheul, R, Bouwstra, JA, Jiskoot, W. Adjuvanted, antigen loaded N‐trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant‐ and site‐dependent immunogenicity in mice. Eur J Pharm Sci 2012, 45:475–481.
Kaisho, T, Akira, S. Toll‐like receptors as adjuvant receptors. Biochim Biophys Acta 2002, 1589:1–13.
Nguyen, DN, Mahon, KP, Chikh, G, Kim, P, Chung, H, Vicari, AP, Love, KT, Goldberg, M, Chen, S, Krieg, AM, et al. Lipid‐derived nanoparticles for immunostimulatory RNA adjuvant delivery. Proc Natl Acad Sci USA 2012, 109:E797–E803.
Tamayo, I, Irache, JM, Mansilla, C, Ochoa‐Reparaz, J, Lasarte, JJ, Gamazo, C. Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll‐like receptor exploitation. Clin Vaccine Immunol 2010, 17:1356–1362.
Castillo, PM, Herrera, JL, Fernandez‐Montesinos, R, Caro, C, Zaderenko, AP, Mejías, JA, Pozo, D. Tiopronin monolayer‐protected silver nanoparticles modulate IL‐6 secretion mediated by Toll‐like receptor ligands. Nanomedicine (Lond) 2008, 3:627–635.
Chithrani, BD, Chan, WC. Elucidating the mechanism of cellular uptake and removal of protein‐coated gold nanoparticles of different sizes and shapes. Nano Lett 2007, 7:1542–1550.
O`Hagan, DT, De Gregorio, E. The path to a successful vaccine adjuvant—‘the long and winding road’. Drug Discov Today 2009, 14:541–551.
Panyam, J, Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55:329–347.
Zolnik, BS, Gonzalez‐Fernandez, A, Sadrieh, N, Dobrovolskaia, MA. Nanoparticles and the immune system. Endocrinology 2010, 151:458–465.
Crisci, E, Barcena, J, Montoya, M. Virus‐like particles: the new frontier of vaccines for animal viral infections. Vet Immunol Immunopathol 2012, 148:211–225.
Tegerstedt, K, Franzen, AV, Andreasson, K, Joneberg, J, Heidari, S, Ramqvist, T, Dalianis, T. Murine polyomavirus virus‐like particles (VLPs) as vectors for gene and immune therapy and vaccines against viral infections and cancer. Anticancer Res 2005, 25:2601–2608.
Cubas, R, Zhang, S, Li, M, Chen, C, Yao, Q. Chimeric Trop2 virus‐like particles: a potential immunotherapeutic approach against pancreatic cancer. J Immunother 2011, 34:251–263.
Fifis, T, Gamvrellis, A, Crimeen‐Irwin, B, Pietersz, GA, Li, J, Mottram, PL, McKenzie, IF, Plebanski, M. Size‐dependent immunogenicity: therapeutic and protective properties of nano‐vaccines against tumors. J Immunol 2004, 173:3148–3154.
Mottram, PL, Leong, D, Crimeen‐Irwin, B, Gloster, S, Xiang, SD, Meanger, J, Ghildyal, R, Vardaxis, N, Plebanski, M. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm 2007, 4:73–84.
Scholer, N, Hahn, H, Muller, RH, Liesenfeld, O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm 2002, 231:167–176.
Shvedova, AA, Kisin, ER, Mercer, R, Murray, AR, Johnson, VJ, Potapovich, AI, Tyurina, YY, Gorelik, O, Arepalli, S, Schwegler‐Berry, D, et al. Unusual inflammatory and fibrogenic pulmonary responses to single‐walled carbon nanotubes in mice. Am J Physiol Lung Cell Mol Physiol 2005, 289:L698–L708.
Vallhov, H, Qin, J, Johansson, SM, Ahlborg, N, Muhammed, MA, Scheynius, A, Gabrielsson, S. The importance of an endotoxin‐free environment during the production of nanoparticles used in medical applications. Nano Lett 2006, 6:1682–1686.
Tan, Y, Li, S, Pitt, BR, Huang, L. The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector‐mediated transgene expression in vivo. Hum Gene Ther 1999, 10:2153–2161.
Carlson, C, Hussain, SM, Schrand, AM, Braydich‐Stolle, LK, Hess, KL, Jones, RL, Schlager, JJ. Unique cellular interaction of silver nanoparticles: size‐dependent generation of reactive oxygen species. J Phys Chem B 2008, 112:13608–13619.
Dominguez, AL, Lustgarten, J. Targeting the tumor microenvironment with anti‐neu/anti‐CD40 conjugated nanoparticles for the induction of antitumor immune responses. Vaccine 2010, 28:1383–1390.
Park, J, Wrzesinski, SH, Stern, E, Look, M, Criscione, J, Ragheb, R, Jay, SM, Demento, SL, Agawu, A, Licona Limon, P, et al. Combination delivery of TGF‐β inhibitor and IL‐2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater 2012, 11:895–905.
Siegel, JP, Puri, RK. Interleukin‐2 toxicity. J Clin Oncol 1991, 9:694–704.
Kanaoka, E, Takahashi, K, Yoshikawa, T, Jizomoto, H, Nishihara, Y, Uchida, N, Maekawa, R, Hirano, K. A significant enhancement of therapeutic effect against hepatic metastases of M5076 in mice by a liposomal interleukin‐2 (mixture). J Control Release 2002, 82:183–187.
Neville, ME, Robb, RJ, Popescu, MC. In situ vaccination against a non‐immunogenic tumour using intratumoural injections of liposomal interleukin 2. Cytokine 2001, 16:239–250.
Skubitz, KM, Anderson, PM. Inhalational interleukin‐2 liposomes for pulmonary metastases: a phase I clinical trial. Anticancer Drugs 2000, 11:555–563.
van Slooten, ML, Storm, G, Zoephel, A, Küpcü, Z, Boerman, O, Crommelin, DJ, Wagner, E, Kircheis, R. Liposomes containing interferon‐γ as adjuvant in tumor cell vaccines. Pharm Res 2000, 17:42–48.
Libutti, SK, Paciotti, GF, Byrnes, AA, Alexander, HR Jr, Gannon, WE, Walker, M, Seidel, GD, Yuldasheva, N, Tamarkin, L. Phase I and pharmacokinetic studies of CYT‐6091, a novel PEGylated colloidal gold‐rhTNF nanomedicine. Clin Cancer Res 2010, 16:6139–6149.
Yanase, M, Shinkai, M, Honda, H, Wakabayashi, T, Yoshida, J, Kobayashi, T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: an in vivo study. Jpn J Cancer Res 1998, 89:463–469.
Hu, KW, Huang, CC, Hwu, JR, Su, WC, Shieh, DB, Yeh, CS. A new photothermal therapeutic agent: core‐free nanostructured Au x Ag1‐x dendrites. Chemistry 2008, 14:2956–2964.
Hirsch, LR, Stafford, RJ, Bankson, JA, Sershen, SR, Rivera, B, Price, RE, Hazle, JD, Halas, NJ, West, JL. Nanoshell‐mediated near‐infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA 2003, 100:13549–13554.
Torti, SV, Byrne, F, Whelan, O, Levi, N, Ucer, B, Schmid, M, Torti, FM, Akman, S, Liu, J, Ajayan, PM, et al. Thermal ablation therapeutics based on CN(x) multi‐walled nanotubes. Int J Nanomedicine 2007, 2:707–714.
Gannon, CJ, Cherukuri, P, Yakobson, BI, Cognet, L, Kanzius, JS, Kittrell, C, Weisman, RB, Pasquali, M, Schmidt, HK, Smalley, RE, et al. Carbon nanotube‐enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer 2007, 110:2654–2665.
Todryk, SM, Melcher, AA, Dalgleish, AG, Vile, RG. Heat shock proteins refine the danger theory. Immunology 2000, 99:334–337.
Asea, A, Rehli, M, Kabingu, E, Boch, JA, Bare, O, Auron, PE, Stevenson, MA, Calderwood, SK. Novel signal transduction pathway utilized by extracellular HSP70: role of toll‐like receptor (TLR) 2 and TLR4. J Biol Chem 2002, 277:15028–15034.
Vabulas, RM, Ahmad‐Nejad, P, Ghose, S, Kirschning, CJ, Issels, RD, Wagner, H. HSP70 as endogenous stimulus of the Toll/interleukin‐1 receptor signal pathway. J Biol Chem 2002, 277:15107–15112.
Suzue, K, Zhou, X, Eisen, HN, Young, RA. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc Natl Acad Sci USA 1997, 94:13146–13151.
Todryk, S, Melcher, AA, Hardwick, N, Linardakis, E, Bateman, A, Colombo, MP, Stoppacciaro, A, Vile, RG. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 1999, 163:1398–1408.
Moroi, Y, Mayhew, M, Trcka, J, Hoe, MH, Takechi, Y, Hartl, FU, Rothman, JE, Houghton, AN. Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Proc Natl Acad Sci USA 2000, 97:3485–3490.
Noessner, E, Gastpar, R, Milani, V, Brandl, A, Hutzler, PJ, Kuppner, MC, Roos, M, Kremmer, E, Asea, A, Calderwood, SK, et al. Tumor‐derived heat shock protein 70 peptide complexes are cross‐presented by human dendritic cells. J Immunol 2002, 169:5424–5432.
Ito, A, Shinkai, M, Honda, H, Wakabayashi, T, Yoshida, J, Kobayashi, T. Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer Immunol Immunother 2001, 50:515–522.
Ostberg, JR, Dayanc, BE, Yuan, M, Oflazoglu, E, Repasky, EA. Enhancement of natural killer (NK) cell cytotoxicity by fever‐range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells. J Leukoc Biol 2007, 82:1322–1331.
Maeda, H, Sawa, T, Konno, T. Mechanism of tumor‐targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 2001, 74:47–61.